Victoria Wittner
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Victoria Wittner has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
- Mari Angelica S. Cayabyab
Department of Pharmacy Hospital of the University of Pennsylvania Philadelphia Pennsylvania USA
5 shared publications - Sony Tuteja
Division of Translational Medicine and Human Genetics, Department of Medicine Perelman School of Medicine Philadelphia Pennsylvania USA
5 shared publications - Glenda Hoffecker
Department of Pharmacy Hospital of the University of Pennsylvania Philadelphia Pennsylvania USA
4 shared publications - Jean De Dieu Ndayishimiye
Division of Translational Medicine and Human Genetics, Department of Medicine, Perelman School of Medicine, Philadelphia, PA
2 shared publications Ursina R. Teitelbaum
Division of Hematology/Oncology Perelman School of Medicine at the University of Pennsylvania Philadelphia Pennsylvania USA
2 shared publicationsXingmei Wang
Center for Clinical Epidemiology and Biostatistics Perelman School of Medicine at the University of Pennsylvania Philadelphia Pennsylvania USA
2 shared publications
Latest Publications
- Open Access
- 31 October 2026
- Published by Wiley in Clinical and Translational Science
- Vol. 19 (11)
Defining Core Functions and Forms for the Implementation of Pharmacogenomics Testing in Primary Care
Pharmacogenomics (PGx), utilizing a patient's DNA to individualize medication prescribing, minimizes adverse events and improves patient outcomes. However, the integration of PGx into primary care remains sparse. PGx testing encompasses multiple components and can be considered a complex health intervention. We conducted an in‐person workshop with early adopters from the Pharmacogenomics Global Research Network Implementation Working Group, followed by qualitative interviews with key opinion leaders, to identify the core functions and forms necessary for implementing PGx testing in primary care. Workshop participants agreed on six core functions necessary to implement PGx‐guided medication prescribing in primary care settings: patient identification, test ordering, laboratory testing, returning results, providing medication recommendations, and modifying pharmacotherapy. An additional function, leadership engagement, was proposed by key opinion leaders. There was considerable variation in the forms, depending on local context and available resources. In this position paper, we discuss why it is critical to separately define the core functions required to implement PGx testing in primary care settings and the customizable forms used for local execution. Defining core functions provides an actionable first step to guide scalable and context‐sensitive integration of PGx testing into routine primary care practice, balancing the need for both fidelity and adaptation in real‐world implementation.
- 31 October 2026
- Published by Wiley in Clinical and Translational Science
- Vol. 19 (11)
Open AccessDefining Core Functions and Forms for the Implementation of Pharmacogenomics Testing in Primary Care
Pharmacogenomics (PGx), utilizing a patient's DNA to individualize medication prescribing, minimizes adverse events and improves patient outcomes. However, the integration of PGx into primary care remains sparse. PGx testing encompasses multiple components and can be considered a complex health intervention. We conducted an in‐person workshop with early adopters from the Pharmacogenomics Global Research Network Implementation Working Group, followed by qualitative interviews with key opinion leaders, to identify the core functions and forms necessary for implementing PGx testing in primary care. Workshop participants agreed on six core functions necessary to implement PGx‐guided medication prescribing in primary care settings: patient identification, test ordering, laboratory testing, returning results, providing medication recommendations, and modifying pharmacotherapy. An additional function, leadership engagement, was proposed by key opinion leaders. There was considerable variation in the forms, depending on local context and available resources. In this position paper, we discuss why it is critical to separately define the core functions required to implement PGx testing in primary care settings and the customizable forms used for local execution. Defining core functions provides an actionable first step to guide scalable and context‐sensitive integration of PGx testing into routine primary care practice, balancing the need for both fidelity and adaptation in real‐world implementation.
- Open Access
- 6 January 2026
- Published by Wiley in Clinical and Translational Science
- Vol. 19 (1) , e70459
Consent, Concern, and Capacity: Factors Associated With Attitudes Toward Pharmacogenetic Testing Among Patients With Gastrointestinal Cancer
Pharmacogenetics (PGx) applies knowledge of drug‐gene interactions to maximize effectiveness and reduce toxicity of medications. PGx impacts the dosing of chemotherapy for gastrointestinal cancer, including fluoropyrimidines and irinotecan. However, pretreatment PGx testing is not routinely implemented due to barriers, including insufficient data surrounding counseling practices. This study assessed genetics knowledge and PGx attitudes in patients with gastrointestinal cancers. A survey was distributed to Penn Medicine Biobank and IMPACT‐GI participants. Multivariable analysis was conducted to assess the influence of genetics knowledge and patient characteristics on attitudes toward PGx. 132 participants completed the survey, 69 (52%) female, 22 (17%) non‐White, 50 (38%) colorectal and 40 (30%) pancreatic cancers. The mean genetics knowledge score was 2.67 ± 1.14 correct responses out of 4. Willingness to undergo pharmacogenetic testing was associated with higher genetics knowledge ( β = 0.6, 95% CI [0.1, 1.0], p = 0.0132), being female ( β = 1.1, 95% CI [0.0, 2.2], p = 0.0435), and higher self‐reported health literacy ( β = 2.2, 95% CI [0.9, 3.5], p < 0.001). Participants were less willing to undergo testing if they had health insurance concerns ( β = −3.7, 95% CI [−5.8, −1.7], p < 0.001) or did not complete secondary education ( β = −2.0, 95% CI [−3.5, −0.6], p = 0.006). Patients preferred providers to obtain consent and explain PGx's utility before testing. These findings provide initial patient‐informed guidance for the implementation of pharmacogenetic testing in gastrointestinal cancer care and identify targets for patient education. As all survey respondents were research‐engaged and from a single institution, the study population may not be widely generalizable.
- 6 January 2026
- Published by Wiley in Clinical and Translational Science
- Vol. 19 (1) , e70459
Open AccessConsent, Concern, and Capacity: Factors Associated With Attitudes Toward Pharmacogenetic Testing Among Patients With Gastrointestinal Cancer
Pharmacogenetics (PGx) applies knowledge of drug‐gene interactions to maximize effectiveness and reduce toxicity of medications. PGx impacts the dosing of chemotherapy for gastrointestinal cancer, including fluoropyrimidines and irinotecan. However, pretreatment PGx testing is not routinely implemented due to barriers, including insufficient data surrounding counseling practices. This study assessed genetics knowledge and PGx attitudes in patients with gastrointestinal cancers. A survey was distributed to Penn Medicine Biobank and IMPACT‐GI participants. Multivariable analysis was conducted to assess the influence of genetics knowledge and patient characteristics on attitudes toward PGx. 132 participants completed the survey, 69 (52%) female, 22 (17%) non‐White, 50 (38%) colorectal and 40 (30%) pancreatic cancers. The mean genetics knowledge score was 2.67 ± 1.14 correct responses out of 4. Willingness to undergo pharmacogenetic testing was associated with higher genetics knowledge ( β = 0.6, 95% CI [0.1, 1.0], p = 0.0132), being female ( β = 1.1, 95% CI [0.0, 2.2], p = 0.0435), and higher self‐reported health literacy ( β = 2.2, 95% CI [0.9, 3.5], p < 0.001). Participants were less willing to undergo testing if they had health insurance concerns ( β = −3.7, 95% CI [−5.8, −1.7], p < 0.001) or did not complete secondary education ( β = −2.0, 95% CI [−3.5, −0.6], p = 0.006). Patients preferred providers to obtain consent and explain PGx's utility before testing. These findings provide initial patient‐informed guidance for the implementation of pharmacogenetic testing in gastrointestinal cancer care and identify targets for patient education. As all survey respondents were research‐engaged and from a single institution, the study population may not be widely generalizable.
- Open Access
- 8 November 2025
- Published by Elsevier in Journal of the American Pharmacists Association
- Vol. 66 (1) , 102990
Patient and provider perspectives on the implementation of DPYD testing in oncology care clinics in an academic health system
- 8 November 2025
- Published by Elsevier in Journal of the American Pharmacists Association
- Vol. 66 (1) , 102990
Open AccessPatient and provider perspectives on the implementation of DPYD testing in oncology care clinics in an academic health system
- Open Access
- 1 August 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 9 (9) , e2500086
Implementation of DPYD and UGT1A1 Testing in Patients With GI Cancer: A Prospective, Nonrandomized Clinical Trial
PURPOSE: To determine the feasibility and effectiveness of implementing pretreatment DPYD/UGT1A1 testing in patients with gastrointestinal cancer and its impact compared with a biobank population. MATERIALS AND METHODS: A prospective, nonrandomized implementation trial of pretreatment DPYD/UGT1A1 testing with preemptive dose reduction was conducted in patients initiating treatment with a fluoropyrimidine (FP, [fluorouracil or capecitabine]) or irinotecan. The primary end point was feasibility, defined as proportion of results available prior to cycle 1 of treatment. Secondarily, occurrence of severe treatment-related adverse events (TRAEs), defined as toxicity resulting in hospitalization or emergency department visit, was compared with a biobank population receiving standard dose chemotherapy. RESULTS: Of the 288 patients prospectively tested, 225 (median age 60.7 years, 54% male, 18% Black, 47% colorectal cancer) received a qualifying chemotherapy. Eight of 11 DPYD variant carriers received an FP and eight of 39 UGT1A1 poor metabolizers received irinotecan. The median test turnaround time was 10 days (IQR, 9-13) with 57.4% of results available before cycle 1. Eleven of 16 (69%) participants with a drug-gene interaction (DGI) had results available before chemotherapy initiation and received pharmacogenetic-recommended dose reductions. Compared with the biobank cohort (n = 229), the prospective DGI group experienced fewer severe TRAEs (38% v 65%, P = .123), treatment discontinuations (31% v 47%, P = .356), and treatment modifications (38% v 76%, P = .028). CONCLUSION: Pretreatment DPYD/UGT1A1 testing and dose reduction was feasible, enabling clinicians to make the appropriate chemotherapy dose reductions, reducing occurrence of adverse outcomes. DPYD/UGT1A1 testing is an important precision oncology approach to optimize patient safety.
- 1 August 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 9 (9) , e2500086
Open AccessImplementation of DPYD and UGT1A1 Testing in Patients With GI Cancer: A Prospective, Nonrandomized Clinical Trial
PURPOSE: To determine the feasibility and effectiveness of implementing pretreatment DPYD/UGT1A1 testing in patients with gastrointestinal cancer and its impact compared with a biobank population. MATERIALS AND METHODS: A prospective, nonrandomized implementation trial of pretreatment DPYD/UGT1A1 testing with preemptive dose reduction was conducted in patients initiating treatment with a fluoropyrimidine (FP, [fluorouracil or capecitabine]) or irinotecan. The primary end point was feasibility, defined as proportion of results available prior to cycle 1 of treatment. Secondarily, occurrence of severe treatment-related adverse events (TRAEs), defined as toxicity resulting in hospitalization or emergency department visit, was compared with a biobank population receiving standard dose chemotherapy. RESULTS: Of the 288 patients prospectively tested, 225 (median age 60.7 years, 54% male, 18% Black, 47% colorectal cancer) received a qualifying chemotherapy. Eight of 11 DPYD variant carriers received an FP and eight of 39 UGT1A1 poor metabolizers received irinotecan. The median test turnaround time was 10 days (IQR, 9-13) with 57.4% of results available before cycle 1. Eleven of 16 (69%) participants with a drug-gene interaction (DGI) had results available before chemotherapy initiation and received pharmacogenetic-recommended dose reductions. Compared with the biobank cohort (n = 229), the prospective DGI group experienced fewer severe TRAEs (38% v 65%, P = .123), treatment discontinuations (31% v 47%, P = .356), and treatment modifications (38% v 76%, P = .028). CONCLUSION: Pretreatment DPYD/UGT1A1 testing and dose reduction was feasible, enabling clinicians to make the appropriate chemotherapy dose reductions, reducing occurrence of adverse outcomes. DPYD/UGT1A1 testing is an important precision oncology approach to optimize patient safety.
- Open Access
- 15 August 2024
- Published by Wiley in Clinical and Translational Science
- Vol. 17 (8) , e70003
A call for reporting of tumor‐specific outcomes in studies of DPYD genotyping
- 15 August 2024
- Published by Wiley in Clinical and Translational Science
- Vol. 17 (8) , e70003
Open AccessA call for reporting of tumor‐specific outcomes in studies of DPYD genotyping